Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical‐only ER‐positive breast cancer

Abstract

Tamoxifen treatment is important assistant for estrogen‐receptor‐positive breast cancer (BRCA) after resection. This study aimed to identify signatures for predicting the prognosis of patients with BRCA after tamoxifen treatment. Data of gene‐specific DNA methylation (DM), as well as the corresponding clinical data for the patients with BRCA, were obtained from The Cancer Genome Atlas and followed by systematic bioinformatics analyses. After mapping these DM CPG sites onto genes, we finally obtained 352 relapse‐free survival (RFS) associated DM genes, with which 61,776 gene pairs were combined, including 1,614 gene pairs related to RFS. An 11 gene‐pair signature was identified to cluster the 189 patients with BRCA into the surgical low‐risk group (136 patients) and high‐risk group (53 patients). Then, we further identified a tamoxifen‐predictive signature that could classify surgical high‐risk patients with significant differences on RFS. Combining surgical‐only prognostic signature and tamoxifen‐predictive signature, patients were clustered into surgical‐only low‐risk group, tamoxifen nonbenefit group, and tamoxifen benefit group. In conclusion, we identified that the gene pair PDHA2–APRT could serve as a potential prognostic biomarker for patients with BRCA after tamoxifen treatment.

Pairwise correlation of genes involved in glucose metabolism: a potential diagnostic marker of cancer?

“…However, the biological function of PDHA2 has barely been studied in cancer cells. Only recently, Lv et al proposed gene pair PDHA2-APRT as a potential prognostic marker for breast cancer patients after treatment with tamoxifen [ 27 ].…”

<p>¹⁸F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model</p>

“…As reported in cancer statistics, breast cancer (BC) is one of the most common female malignancies worldwide and the leading cause of cancer-related mortality among women globally, ranking first in prevalence and second in mortality. 1 With the development of early diagnostic techniques and the emergence of more effective molecular targeted therapeutic drugs, such as tamoxifen 2 and trastuzumab, 3 the efficiency of breast cancer treatment has improved and the survival rate for breast cancer patients has increased markedly during the past decades. 4,5 However, to further improve the efficiency of breast cancer treatment is a new challenge due to the development of treatment resistance and side effects.…”